• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
The 'Press Releases' section offers the latest product-specific and company-related updates to our esteemed clients, providing them with a valuable resource. Members can leverage this platform for quick, efficient, and effective visibility.

— Our press release programs complement our content distribution initiatives, ensuring strong positioning across major media outlets and social media channels. This enhances the visibility of your message within the global pharmaceutical industry.

ImmuneOncia Announces Biomarker Results from Phase 1 Clinical Trial of CD47 Antibody

ImmuneOncia announced the results of its solid tumour Phase 1a clinical trial of IMC-002, an anti-CD47 mAb.These results include updates on the Phase 1a clinical trial outcomes, along with biomarker findings achieved through collaboration with Lunit (CEO; Brandon Suh), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics.

Read more →
The Virtual Ports maneuvering system

Virtual-Ports Receives CE Certification for Revolutionary Surgical Devices

Virtual-Ports Ltd is thrilled to announce the attainment of CE certification under the new MDR for its groundbreaking surgical products. Renowned for their single-hand, multi-application design, Virtual-Ports' solutions are set to revolutionize abdominal surgery by significantly improving visibility and access within the surgical space.

Read more →

Apotex Corp. Introduces Generic Fertility Treatment Injectable Cetrorelix® in the United States

Apotex Corp. announced  Cetrorelix Acetate for Injection 0.25mg, a generic version of Cetrotide® in the United States .Cetrorelix Acetate for Injection is a synthetic decapeptide with gonadotrophin-releasing hormone (GnRH) antagonist, indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.

"This launch provides American women access to affordable fertility treatments," said Christine Baeder, President, Apotex Corp. "It demonstrates our unwavering focus on meeting patient needs with high-quality medication that is more accessible to everyone."

 Small Cell Lung Cancer

SN Bioscience Granted FDA Fast Track Designation for Small Cell Lung Cancer Treatment

SN Bioscience Co. Ltd. announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a new drug for polymer nanoparticle anticancer under clinical trial. SNB-101 was designated as an orphan drug for small cell lung cancer and pancreatic cancer in July of last year and February of this year, respectively. By receiving fast-track designation this time, it is evaluated that it has laid the groundwork that can be commercialized immediately after completion of phase 2 clinical trials.

Read more →
Cytovance Biologics

ExcellGene SA and Cytovance Biologics Partner to Revolutionize Large Molecule Biologics Development and Manufacturing

ExcellGene SA, a leading Swiss biotech service provider specializing in mammalian cell line development for more than two decades, proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization (CDMO) based in the USA.

Read more →
Mechanism of LBL-024

Leads Biolabs' LBL-024: CDE Approved Pivotal Clinical Study for Potential First-in-Class Anti-PD-L1/4-1BB Bispecific Antibody

Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by Leads Biolabs with global intellectual property rights has received approval to conduct the single-arm pivotal study for registration and market.

Read more →